NCT00187525已完成4 期
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
研究概览
简要总结
This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Neary et al. Criteria for Frontotemporal Lobar Degeneration
- •Age 40 -80
- •CDR < 3 or MMSE > 15
- •English Speaking
- •Study Partner
排除标准
- •Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors
研究者
相似试验
已完成
1 期
A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State MemantineHealthy VolunteerNCT01196065Hoffmann-La Roche16
招募中
不适用
An open-label trial of memantine for the treatment of posttraumatic stress disorderposttraumatic stress disorderJPRN-jRCTs031180200Kim Yoshiharu20
已完成
不适用
An open-label trial of memantine for the treatment of posttraumatic stress disorderJPRN-UMIN000022467ational Institute of Mental Health, National Center of Neurology and Psychiatry20
已完成
4 期
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOSADHDNCT00586573Massachusetts General Hospital34
已完成
2 期
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With AutismAutismNCT00872898Forest Laboratories124